Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

The significant unmet needs in OA treatment gives pharma companies the opportunity to create novel DMOADs, says GlobalData

There is a high level of unmet medical needs in the Osteoarthritis (OA) market such as the lack of disease-modifying OA drugs (DMOADs) and the need for effective analgesics with fewer adverse effects. This provides pharmaceutical companies with the opportunity to develop new drugs with disease-modifying effects and novel methods of action (MOAs) that are […]
Read more

Sanofi and Regeneron’s additional label expansion for Dupixent reinforces its dominance in the atopic dermatitis market, says GlobalData

The Food and Drug Administration’s (FDA) approval for Sanofi and Regeneron’s interleukin (IL)-4/13 inhibitor, Dupixent (dupilumab), for the treatment of children ages 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) earlier this month, has solidified first-mover advantage for Dupixent and reinforces its market-leading position for the treatment of moderate-to-severe AD, says GlobalData, a […]
Read more

Multiple myeloma patients in China close to getting first homegrown CAR-T cell therapy, says GlobalData

Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma is not yet available in China. However, the China National Medical Products Administration (NMPA) has recently accepted the new drug application (NDA) for Innovent and IASO Biotherapeutics’ CAR-T therapy equecabtagene autoleucel to treat relapsed and/or refractory multiple myeloma (R/R MM). Following the approval, it will be […]
Read more

India’s first domestically produced HPV vaccine by SII to improve affordability for those most at need, says GlobalData

Serum Institute of India’s (SII) Cervavac—a quadrivalent human papillomavirus (qHPV) vaccine— is likely to be the first indigenous qHPV vaccine to be approved in India, according to GlobalData. The leading data and analytics company notes that this will not only make the drug more affordable to Indians, but it will significantly improve the overall penetration […]
Read more

CStone sugemalimumab to face stiff competition in NSCLC segment in China, says GlobalData

The National Medical Products Administration (NMPA) of China has recently approved CStone Pharmaceuticals’ sugemalimumab (Cejemly) to treat patients with stage III non-small cell lung cancer (NSCLC), whose disease has not progressed following concurrent or sequential or platinum-based chemoradiotherapy. Against this backdrop, sugemalimumab will still face stiff competition in China, observes GlobalData, a leading data and […]
Read more

Biological E. has carved out its place in India’s COVID-19 vaccine market following Corbevax’s approval, says GlobalData

The Drugs Controller General of India (DCGI) recently approved Biological E.’s Corbevax vaccine as the first heterogeneous COVID-19 booster vaccine in India for adults above 18 years who have received two shots of Covaxin or Covishield. Corbevax has the added advantage of scalability and thermostability, making it suitable for deployment in low-resource settings, says GlobalData. […]
Read more

Digital campaigns hoped to boost breast cancer awareness in India as country to see third-highest rise in cases worldwide, says GlobalData

Out of 16 markets worldwide*, India saw the third-highest rise in total HER2+ breast cancer cases, according to GlobalData. The leading data and analytics company notes that the country is expected to see total incident cases increase from 255,749 in 2022 to 311,128 by 2030 at an annual growth rate (AGR) of 2.84%. GlobalData highlights […]
Read more

Oxurion NV’s THR-149 has potential to address key unmet need in the ophthalmology market, says GlobalData

Preclinical research for Oxurion NV’s THR-687 was presented at the Association for Research in Ophthalmology (ARVO) last month, forecasting its promising potential within the DME space. However, Oxurion NV recently announced it would no longer pursue its Phase IIb INTEGRAL for THR-687 for the treatment of diabetic macular edema (DME), stating its decision to progress […]
Read more

WatchOS 9’s long-anticipated key workout and health features will continue to ensure Apple’s domination of the wearables market, says GlobalData

Following the announcement of WatchOS 9 during Apple’s 2022 WWDC event; Ardit Ballhysa, Technology Analyst at GlobalData, a leading data and analytics company, offers his view: “This year’s WatchOS update focuses heavily on staying ‘active and healthy’, two elements that are paramount to the success of a wearable device. “WatchOS 9 builds on the Workout […]
Read more

Smart pacifiers in development will be helpful for infants in the NICU as they reduce the need for bloodwork, says GlobalData

Following the news that researchers from Washington State University have developed a smart pacifier to monitor newborn infants; Alexandra Murdoch, Medical Device Analyst at GlobalData, a leading data and analytics company offers her view: “This device will be especially helpful for babies who are in the neonatal intensive care unit (NICU), as they are at […]
Read more

MVA-BN respiratory syncytial virus vaccine could get first-to-market opportunity in China, says GlobalData

Bavarian Nordic has recently announced an exclusive license and supply agreement with China’s Nuance Pharma to develop and commercialize their candidate MVA-BN respiratory syncytial virus (RSV) vaccine in adults in China Mainland, Hong Kong, Macau, Taiwan, South Korea, and Southeast Asian countries. Leveraging Nuance Pharma’s local presence could provide a unique first-to-market opportunity for MVA-BN […]
Read more

Borrena (lorlatinib) approval further strengthens Pfizer position in China NSCLC market, says GlobalData

The National Medical Products Administration (NMPA) of China has recently approved Pfizer’s third generation ALK inhibitor Borrena (lorlatinib) as the first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Pfizer already has deep commercial experience in China’s NSCLC market, and this approval will further strengthen its position within the […]
Read more

Alpha-1 Antitrypsin Deficiency market to reach $3.48 billion in 2031 driven by entrance of several novel therapies, says GlobalData

An upcoming influx of new therapies into the Alpha-1 Antitrypsin Deficiency (AATD) space in the next decade is expected to provide a significant boost to the treatment market for this inherited disorder that can greatly damage both lung and liver function, found GlobalData. According to the leading data and analytics company, the two major markets* […]
Read more

UCB is well-positioned to become a key player in the myasthenia gravis market with zilucoplan and rozanolixizumab, says GlobalData

Positive Phase III trial results from UCB’s two clinical trials in its generalized myasthenia gravis (gMG) program will enable it to become a key future player in the MG market, with both zilucoplan and rozanolixizumab expected to enter the market next year, says GlobalData, a leading data and analytics company. Philippa Salter, Neurology Analyst at […]
Read more
1 … 45 46 47 48 49 … 108